Companies in fourth cohort developing products ranging from software to therapeutic platforms; applications for fifth cohort, in partnership with MLA48, open until May 27, 2016
TORONTO (May 9, 2016) — The University of Toronto Early-Stage Technology (UTEST) incubator, co-directed by U of T’s Innovations & Partnerships Office (IPO) and MaRS Innovation with financial support from the Connaught Fund, has announced five investments in start-up companies from Cohort 4.
The five companies and the diverse sectors they target are:
Ardra Bio, which is ...
Montreal-based venture capital fund and entrepreneurship program brings over $20 million in funding and deep expertise in consumer electronics to MI members; first deal in speech recognition
TORONTO and MONTREAL, (May 3, 2016) — MaRS Innovation, the commercialization agent for fifteen of Toronto’s top academic institutions, and TandemLaunch, a Montreal-based venture capital fund and startup incubator that specializes in consumer electronics have formed a strategic partnership (see the Areas of Interest chart below for examples). The partnership will co-develop promising technology emerging ...
It’s been a busy quarter for UTEST company TrendMD. Fresh off their participation in Ycombinator’s Winter 2016 cohort, which was covered in TechCrunch, the company has announced partnerships with HighWire and Integra.
TrendMD, a Canadian start-up company, is a content recommendation engine for scholarly publishers. They work with over 2,000 medical journals by organizing and tailoring information to the appropriate audiences. This functionality creates several opportunities for various researchers to promote their research and clinical practices in their respective fields.
TrendMD launched through ...
Company initiating two new clinical trials for recurrent and newly diagnosed malignant gliomas
TORONTO and SAN DIEGO, (May 03, 2016) – Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it is expanding its current collaboration with Celgene Corp. in the development of marizomib for the potential treatment of malignant gliomas.
The two companies will collaborate on a Phase 2 study using marizomib (MRZ) as monotherapy in recurrent glioblastoma, as well as a Phase ...
"Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S.," Leonard Zahr wrote in a feature article on Xagenic's product development progress for BioTuesdays on April 19, 2016.
Xagenic was founded by University of Toronto Professor Shana Kelley in partnership with MaRS Innovation and U of T's Innovations & Partnerships Office in 2010. The company ...
Results for results in docetaxel-resistant prostate cancer models presented at the American Association for Cancer Research (AACR) Conference
TORONTO and SAN DIEGO (April 18, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, and the Ontario Institute for Cancer Research (OICR), today announced positive results from a preclinical study of their CBZed-Nano™ (cabazitaxel cellulose nanoparticle) product in docetaxel-resistant prostate cancer mouse models. Preliminary results also showed that the nanoparticles accumulate in intracranial brain ...
Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017
HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto (“XOR”), a spin-off of Toronto General Hospital at University Health Network (UHN), the world’s leading center for lung transplantation, created in partnership with MaRS Innovation.
This announcement was covered in FierceMedicalDevices and Cystic Fibrosis News Today.
VICE featured XOR's life-saving lung transplant technology ...
MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
Applications for next MSc PoP granting round being accepted until February 25, 2016
TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children.
Applications for the next MSc PoP granting round are open until March 4, 2016. To ...